A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 for Injection Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cance

Title: A Phase III Randomized Controlled Clinical Study Comparing BL-B01D1 for Injection Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cance NCT ID: NCT07502300 Phase: PHASE3 Status: NOT_YET_RECRUITING Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Conditions: Extensive-stage Small-cell Lung Cancer Interventions: BL-B01D1, Tislelizumab, Carboplatin, Etoposide Enrollment: 562 ESTIMATED Summary: This trial is a registrational Phase III, randomized, open-label, multicenter study to compare the efficacy and safety of BL-B01D1 in combination with tislelizumab versus platinum-based chemotherapy in combination with tislelizumab in first-line patients with extensive-stage small cell lung cancer.